# EASTERNMED FUNDS VCIC PLC

## INTERIM FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 JUNE 2026

# EASTERNMED FUNDS VCIC PLC

INTERIM FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED 30 JUNE 2026

CONTENTS


| | PAGE |
|---|---|
| Board of Directors and other officers | 1 |
| Unaudited statement of profit or loss and other comprehensive income | 2 |
| Unaudited statement of financial position | 3 |
| Unaudited statement of net assets attributable to holders of investor shares | 4 |
| Unaudited statement of cash flows | 5 |
| Notes to the unaudited financial statements | 6 - 15 |

# EASTERNMED FUNDS VCIC PLC

## BOARD OF DIRECTORS AND OTHER OFFICERS

| | |
|---|---|
| **Board of Directors:** | Athanasios J. Martinos<br>Andreas Theophanous<br>Ioannis Papaioannou<br>Stavros A. Karides<br>Maria Panayi Drakos |
| **Secretary:** | K and K Secretarial Limited<br>11 Kyriakou Matsi Street, Nikis Center, 8th floor<br>1082 Nicosia<br>Cyprus |
| **Management Company:** | Easternmed Asset Management Services Ltd<br>11 Kyriakou Matsi Street, Nikis Center, 8th floor<br>1082 Nicosia<br>Cyprus |
| **Fund Administration:** | MFO Asset Management Ltd<br>66 Acropolis Avenue, Acropolis Tower, 1st floor<br>2012 Nicosia<br>Cyprus |
| **External Auditors:** | BDO Limited<br>236 Strovolou Avenue<br>2048 Strovolos<br>Cyprus |
| **External Legal Advisers:** | Karides & Karides LLC<br>11 Kyriakou Matsi Street, Nikis Center, 8th floor<br>1082 Nicosia<br>Cyprus |
| **Registered office:** | 48 Themistokli Dervi Avenue<br>Athienitis Centennial Building, Office 104<br>1066 Nicosia<br>Cyprus |
| **Depositary:** | Bank of Cyprus Public Company Ltd<br>51 Stasinou Street<br>1398 Nicosia<br>Cyprus |
| **Registration number:** | HE354779 |

# EASTERNMED FUNDS VCIC PLC

## UNAUDITED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
FOR THE SIX MONTHS ENDED 30 JUNE 2026

| | Note | **Easternmed Equities Fund Class A 30 June 2026 €** | Easternmed Equities Fund Class A 30 June 2025 € |
|---|---|---|---|
| **Revenue** | | | |
| Dividend income | | **12.573.050** | 14.547.624 |
| Interest income | 6 | **585.988** | 437.707 |
| Net realised gains on financial assets at fair value through profit or loss | 8 | **10.446.103** | 1.197.354 |
| Net unrealised gains on financial assets at fair value through profit or loss | 7 | **38.443.028** | 12.676.428 |
| Net foreign currency gains/(losses) | | **948.613** | (866.946) |
| Other operating income | | **16.702** | 15.868 |
| **Total revenue** | | **63.013.484** | 28.008.035 |
| **Operating expenses** | | | |
| Management fees | | **(483.920)** | (385.362) |
| Depositary fees | | **(132.298)** | (107.601) |
| Administration fees | | **(32.500)** | (32.500) |
| Directors' fees | | **(4.785)** | (4.785) |
| Transaction costs | | **(207.363)** | (169.957) |
| Auditors' remuneration | | **(4.344)** | (4.344) |
| Secretarial fees | | **(2.380)** | (2.380) |
| Licences and annual contributions | | **(900)** | (900) |
| Sundry expenses | | **(288)** | (401) |
| **Total operating expenses** | | **(868.778)** | (708.230) |
| **Operating profit before finance costs** | | **62.144.706** | 27.299.805 |
| Net finance costs | 9 | **(2.871)** | (312) |
| **Increase in net assets attributable to holders of investor shares before tax** | | **62.141.835** | 27.299.493 |
| Tax | 10 | **(1.213.345)** | (1.130.600) |
| **Increase in net assets attributable to holders of investor shares for the period** | | **60.928.490** | 26.168.893 |

# EASTERNMED FUNDS VCIC PLC

## UNAUDITED STATEMENT OF FINANCIAL POSITION
AT 30 JUNE 2026

| | Note | **Easternmed Equities Fund Class A 30 June 2026 €** | Easternmed Equities Fund Class A 31 December 2025 € |
|---|---|---|---|
| **ASSETS** | | | |
| Financial assets at fair value through profit or loss | 12 | **656.527.488** | 583.486.708 |
| Cash and cash equivalents | 13 | **9.588.032** | 13.369.079 |
| Other receivables | 11 | **1.326.536** | 1.079.569 |
| **Total assets** | | **667.442.056** | 597.935.356 |
| **LIABILITIES** | | | |
| Other payables | 15 | **341.705** | 312.070 |
| Current tax liabilities | 16 | **17.565** | 11.466 |
| **Total liabilities (excluding net assets attributable to holders of investor shares)** | | **359.270** | 323.536 |
| **Net assets attributable to holders of investor shares** | 14 | **667.082.786** | 597.611.820 |

On 28 August 2026 the Board of Directors of Easternmed Funds VCIC Plc authorised these financial statements for issue.

..............................
Athanasios J. Martinos
Director

..............................
Ioannis Papaioannou
Director

The notes on pages 6 to 15 form an integral part of these financial statements.

# EASTERNMED FUNDS VCIC PLC

## UNAUDITED STATEMENT OF NET ASSETS ATTRIBUTABLE TO HOLDERS OF INVESTOR SHARES
FOR THE SIX MONTHS ENDED 30 JUNE 2026

| | **Easternmed Equities Fund Class A 30 June 2026 €** | Easternmed Equities Fund Class A 30 June 2025 € |
|---|---|---|
| Balance at 1 January | **597.611.820** | 473.086.971 |
| Increase in net assets attributable to holders of investor shares | **60.928.490** | 26.168.893 |
| **Contributions and redemptions by holders of investor shares:** | | |
| Subscription for Class A investor shares during the period | **8.542.476** | 48.539.628 |
| **Total contributions and redemptions by holders of investor shares** | **8.542.476** | 48.539.628 |
| **Balance at 30 June** | **667.082.786** | 547.795.492 |

The notes on pages 6 to 15 form an integral part of these financial statements.

# EASTERNMED FUNDS VCIC PLC

## UNAUDITED STATEMENT OF CASH FLOWS
FOR THE SIX MONTHS ENDED 30 JUNE 2026

| | Note | **Easternmed Equities Fund Class A 30 June 2026 €** | Easternmed Equities Fund Class A 30 June 2025 € |
|---|---|---|---|
| **CASH FLOWS FROM OPERATING ACTIVITIES** | | | |
| **Increase in net assets attributable to holders of investor shares before tax** | | **62.141.835** | 27.299.493 |
| Adjustments for: | | | |
| Net realised gains on financial assets at fair value through profit or loss | 8 | **(10.446.103)** | (1.197.354) |
| Net unrealised gains on financial assets at fair value through profit or loss | 7 | **(38.443.028)** | (12.676.428) |
| Net foreign currency (gains)/losses | | **(948.613)** | 866.946 |
| Dividend income | | **(12.573.050)** | (14.547.624) |
| Interest income | 6 | **(585.988)** | (437.707) |
| Interest expense | 9 | **2.393** | - |
| | | **(852.554)** | (692.674) |
| **Changes in working capital:** | | | |
| Increase in other payables | | **29.635** | 153.153 |
| **Cash used in operations** | | **(822.919)** | (539.521) |
| Interest received | | **447.194** | 311.264 |
| Dividends received | | **12.341.243** | 13.718.803 |
| Proceeds from sale of financial assets at fair value through profit or loss | | **138.573.257** | 25.845.877 |
| Payments for acquisition of financial assets at fair value through profit or loss | | **(162.547.760)** | (51.918.997) |
| Tax paid | | **(11.481)** | (6.154) |
| Withholding tax paid | | **(1.195.765)** | (1.121.986) |
| **Net cash used in operating activities** | | **(13.216.231)** | (13.710.714) |
| **CASH FLOWS FROM FINANCING ACTIVITIES** | | | |
| Proceeds from issue of investor shares | 14 | **8.488.964** | 29.837.519 |
| Interest paid | | **(2.393)** | - |
| **Net cash generated from financing activities** | | **8.486.571** | 29.837.519 |
| **Net (decrease)/increase in cash and cash equivalents** | | **(4.729.660)** | 16.126.805 |
| Cash and cash equivalents at beginning of the period | | **13.369.079** | 6.010.074 |
| Effect of exchange rate fluctuations on cash held | | **948.613** | (866.946) |
| **Cash and cash equivalents at end of the period** | 13 | **9.588.032** | 21.269.933 |

### 1. Incorporation and principal activities

#### Country of incorporation

Easternmed Funds VCIC Plc (the 'Fund') was incorporated in Cyprus on 19 April 2016 as a public limited liability company under the provisions of the Cyprus Companies Law, Cap. 113. The Fund was granted UCITS license No. UCITS 07/78 by the Cyprus Securities and Exchange Commission on 22 March 2016. Its registered office is at 48 Themistokli Dervi Avenue, Athienitis Centennial Building, Office 104, 1066 Nicosia, Cyprus.

The Fund as an umbrella investment company comprises various sub-funds each relating to a separate investment portfolio of securities, cash and other assets. Separate classes of shares are issued in relation to the sub-funds. The Board of Directors of the Fund may authorise the creation of additional sub-funds/share classes in the future subject to CySEC approval. As of 30 June 2026, there was one sub-fund active, namely the Easternmed Equities Fund Class A (the 'Sub-Fund').

The Sub-Fund is primarily involved in investing in a highly diversified portfolio of equity securities issued by companies listed on major European stock exchanges and on the New York Stock Exchange (NYSE), investment funds and corporate debt securities, with the objective of providing shareholders with long-term capital growth subject to moderate volatility.

The Fund's management is performed by Easternmed Asset Management Services Ltd (the 'Management Company'), with the administration delegated to MFO Asset Management Ltd (the 'Fund Administrator').

#### Unaudited financial statements

The financial statements for the six months ended on 30 June 2025 and 2026 respectively, have not been audited by the external auditors of the Company.

### 2. Material accounting policies

The financial statements, which are presented in Euros, have been prepared in accordance with IFRS Accounting Standards, including International Accounting Standard 34 "Interim Financial Reporting". These interim financial statements do not include all the information required for the full annual financial statements prepared in accordance with IFRS Accounting Standards.

The accounting policies used in the preparation of the financial statements are in accordance with those used in the annual financial statements for the year ended 31 December 2025.

Costs that are incurred during the financial year are anticipated or deferred for interim reporting purposes if, and only if, it is also appropriate to anticipate or defer that type of cost at the end of the financial year.

Corporation tax is calculated based on the expected tax rates for the whole financial year.

These financial statements must be read in conjunction with the annual financial statements for the year ended 31 December 2025.

### 3. New accounting pronouncements

At the date of approval of these financial statements, standards and interpretations were issued by the International Accounting Standards Board (the 'IASB') which were not yet effective. Some of them were adopted by the European Union (the 'EU') and others not yet. The Board of Directors expects that the adoption of these accounting standards in future periods will not have a material effect on the financial statements of the Fund.

### 4. Critical accounting estimates and judgments

The preparation of financial statements in conformity with IFRS Accounting Standards requires the use of certain critical accounting estimates and requires Management to exercise its judgement in the process of applying the Fund's accounting policies. It also requires the use of assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on Management's best knowledge of current events and actions, actual results may ultimately differ from those estimates.

The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below:

- **Fair value of financial assets**

  The fair value of financial instruments that are not traded in an active market is determined by using valuation techniques. The Fund uses its judgment to select a variety of methods and make assumptions that are mainly based on market conditions existing at each reporting date. The fair value of the financial assets available for sale has been estimated based on the fair value of these individual assets.

- **Income taxes**

  Significant judgment is required in determining the provision for income taxes. There are transactions and calculations for which the ultimate tax determination is uncertain during the ordinary course of business. The Fund recognises liabilities for anticipated tax audit issues based on estimates of whether additional taxes will be due. Where the final tax outcome of these matters is different from the amounts that were initially recorded, such differences will impact the income tax and deferred tax provisions in the period in which such determination is made.

### 5. Fair value measurement

The table below analyses financial instruments carried at fair value, by valuation method. The different levels have been defined as follows:

- Level 1 - quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2 - inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- Level 3 - inputs for the asset or liability that are not based on observable market data (unobservable inputs).

| **30 June 2026** | Level 1 | Level 2 | Level 3 | Total |
|---|---|---|---|---|
| | € | € | € | € |
| **Financial assets mandatorily at fair value through profit or loss at inception:** | | | | |
| Equity securities | 484.090.808 | - | - | 484.090.808 |
| Unlisted open-ended investment funds | - | 106.520.872 | - | 106.520.872 |
| Debt securities | 64.401.172 | 1.514.636 | - | 65.915.808 |
| **Total** | **548.491.980** | **108.035.508** | **-** | **656.527.488** |

| 31 December 2025 | Level 1 | Level 2 | Level 3 | Total |
|---|---|---|---|---|
| | € | € | € | € |
| **Financial assets mandatorily at fair value through profit or loss at inception:** | | | | |
| Equity securities | 475.909.083 | - | - | 475.909.083 |
| Unlisted open-ended investment funds | - | 61.549.986 | - | 61.549.986 |
| Debt securities | 44.498.110 | 1.529.529 | - | 46.027.639 |
| Total | 520.407.193 | 63.079.515 | - | 583.486.708 |

**5. Fair value measurement (continued)**

Valuation techniques and the inputs used for the fair value measurements categorised within Level 2 of the fair value hierarchy is given below:

**Debt securities**

Where quoted prices in an active market are available at the measurement date for an identical corporate debt security, those prices are used (Level 1 measurement). The Fund measures instruments quoted in an active market at bid price.

In other cases, the fair value is estimated using the market comparison/discounted cash flow techniques. This considers (i) current or recent quoted prices for identical securities in markets that are not active and (ii) a net present value calculated using discount rates derived from quoted prices of securities with similar maturity and credit rating that are traded in active markets, adjusted by an illiquidity factor.

**Listed equity securities**

Listed equity securities are valued using quoted prices in an active market for an identical instrument (Level 1 measurement).

**Unlisted open-ended investment funds**

The Fund invests in open-ended investment funds, that are open to new investors and allow redemptions at net asset value, and are not quoted in an active market. The fair value of investments in the unlisted open-ended investment funds is determined either using unadjusted NAV (Level 2 measurement) or by applying a discount to the NAV (Level 3 measurement). The unadjusted NAV is used when the units in a fund are redeemable at the reportable NAV at, or approximately at, the measurement date. If this is not the case, then NAV is used as a valuation input and an adjustmentis applied for lack of marketability and restrictions on redemptions. This adjustment is based on management judgement after considering the period of restrictions and the nature of the underlying investments.

There were no transfers between Level 1 and Level 2 in the period.

**6. Interest income**

Interest income is analysed as follows:

| | **Easternmed Equities Fund Class A 30 June 2026** | Easternmed Equities Fund Class A 30 June 2025 |
|---|---|---|
| | **€** | € |
| Cash and cash equivalents | **19.667** | 112.704 |
| Listed debt securities at fair value through profit or loss | **566.321** | 325.003 |
| | **585.988** | 437.707 |

### 7. Net unrealised change on financial assets at fair value through profit or loss

Net unrealised gains on financial assets at fair value through profit or loss is analysed as follows:

| | **Easternmed Equities Fund Class A 30 June 2026 €** | Easternmed Equities Fund Class A 30 June 2025 € |
|---|---|---|
| Equity securities | **39.247.437** | 13.502.236 |
| Unlisted open-ended investment funds | **(625.149)** | (748.803) |
| Debt securities | **(179.260)** | (77.005) |
| | **38.443.028** | 12.676.428 |

The net unrealised gains/(losses) from financial assets at fair value through profit or loss represents the difference between the carrying amount of a financial instrument at the beginning of the reporting period and its carrying amount at the end of the reporting period.

### 8. Net realised change on financial assets at fair value through profit or loss

Net realised gains on financial assets at fair value through profit or loss is analysed as follows:

| | **Easternmed Equities Fund Class A 30 June 2026 €** | Easternmed Equities Fund Class A 30 June 2025 € |
|---|---|---|
| Equity securities | **11.138.481** | 1.186.981 |
| Unlisted open-ended investment funds | **(1.122.181)** | 10.373 |
| Debt securities | **429.803** | - |
| | **10.446.103** | 1.197.354 |

The net realised gains/(losses) on financial assets at fair value through profit or loss represents the difference between the carrying amount of a financial asset at the beginning of the reporting period, or the transaction price if it was purchased in the current reporting period, and its settlement price.

### 9. Finance costs

| | **Easternmed Equities Fund Class A 30 June 2026 €** | Easternmed Equities Fund Class A 30 June 2025 € |
|---|---|---|
| Interest expense | **2.393** | - |
| Sundry finance expenses | **478** | 312 |
| **Finance costs** | **2.871** | 312 |

**10. Tax**

| | **Easternmed Equities Fund Class A 30 June 2026 €** | Easternmed Equities Fund Class A 30 June 2025 € |
|---|---|---|
| Corporation tax | **17.580** | 8.614 |
| Withholding tax | **1.195.765** | 1.121.986 |
| **Charge for the period** | **1.213.345** | 1.130.600 |

The total charge for the year can be reconciled to the accounting profit as follows:

| | **Easternmed Equities Fund Class A 30 June 2026 €** | Easternmed Equities Fund Class A 30 June 2025 € |
|---|---|---|
| Increase in net assets attributable to holders of investor shares before tax | **62.141.835** | 27.299.493 |
| Applicable tax rates | **15,00%** | 12,50% |
| Tax calculated at the applicable tax rates | **9.321.275** | 3.412.437 |
| Tax effect of expenses not deductible for tax purposes | **130.748** | 185.293 |
| Tax effect of allowances and income not subject to tax | **(9.434.443)** | (3.589.116) |
| Withholding tax | **1.195.765** | 1.121.986 |
| **Tax charge** | **1.213.345** | 1.130.600 |

The Fund is subject to corporation tax on taxable profits at the rate of 15% (31 December 2025: 12,5%).

**11. Other receivables**

| | **Easternmed Equities Fund Class A 30 June 2026 €** | Easternmed Equities Fund Class A 31 December 2025 € |
|---|---|---|
| Accrued interest on bank current accounts | **15.160** | - |
| Dividend receivable | **1.311.376** | 1.079.569 |
| | **1.326.536** | 1.079.569 |

### 12. Financial assets at fair value through profit or loss

| | **Easternmed Equities Fund Class A 30 June 2026 €** | Easternmed Equities Fund Class A 31 December 2025 € |
|---|---|---|
| Balance at 1 January | **583.486.708** | 467.014.206 |
| Additions | **161.943.588** | 80.940.894 |
| Contribution in kind | **-** | 18.686.378 |
| Disposals | **(127.469.475)** | (37.559.560) |
| Net fair value gains | **38.443.028** | 54.218.434 |
| Accrued interest change | **123.639** | 186.356 |
| **Balance at 30 June / 31 December** | **656.527.488** | 583.486.708 |

Financial assets at fair value through profit or loss are analysed as follows:

| | **Easternmed Equities Fund Class A 30 June 2026 €** | Easternmed Equities Fund Class A 31 December 2025 € |
|---|---|---|
| **Financial assets at fair value through profit or loss** | | |
| Equity securities | **484.090.808** | 475.909.083 |
| Unlisted open-ended investment funds | **106.520.872** | 61.549.986 |
| Debt securities | **65.915.808** | 46.027.639 |
| | **656.527.488** | 583.486.708 |

The financial assets at fair value through profit or loss are marketable securities and are valued at market value at the close of business on 30 June by reference to Stock Exchange quoted bid prices or over the counter prices. The fair value estimation of the financial assets at fair value through profit or loss is disclosed in notes 4 and 5.

In the statement of cash flows, financial assets at fair value through profit or loss are presented within the section on operating activities as part of changes in working capital. In the statement of profit or loss and other comprehensive income, changes in fair values of financial assets at fair value through profit or loss are recorded in operating income.

### 13. Cash and cash equivalents

For the purposes of the statement of cash flows, the cash and cash equivalents include the following:

| | **Easternmed Equities Fund Class A 30 June 2026 €** | Easternmed Equities Fund Class A 31 December 2025 € |
|---|---|---|
| Cash at bank | **9.588.032** | 13.369.079 |
| | **9.588.032** | 13.369.079 |

### 13. Cash and cash equivalents (continued)

**Cash and cash equivalents by currency:**

| | **Easternmed Equities Fund Class A 30 June 2026 €** | Easternmed Equities Fund Class A 31 December 2025 € |
|---|---|---|
| United States Dollars | **367.847** | 614.512 |
| Euro | **510.021** | 12.299.699 |
| British Pounds | **157.547** | 424.215 |
| Norwegian Krone | **473.767** | 17.537 |
| Swiss Franc | **8.078.850** | - |
| Japanese Yen | **-** | 13.116 |
| | **9.588.032** | 13.369.079 |

### 14. Net assets attributable to holders of investor shares

#### 14.1 Investor shares

The Fund was set up with authorised share capital of 500.000.000 investor shares, no fractions of a share are recognised and each share represents the same percentage holding in the overall assets. The price of each investor share in the Fund, at the time of incorporation, was set at €100, with euro as reference currency.

Investor shares are classified into Class A investor shares and Class B investor shares. The rights and obligations of the two share classes are identical, with the exemption of the subscription, redemption and management fee charge.

The Minimum Holding and Minimum Initial Subscription required for Class A investor shares is €800.000 and the Minimum Additional Subscription required for Class A investor shares is €500.000. The Minimum Holding, Minimum Initial Subscription and Minimum Additional Subscription required for Class B investor shares is €5.000. These minimum initial and additional subscription amounts may be reduced or increased, at the discretion of the Fund, whenever the Fund considers it reasonable or appropriate, taking into consideration the diversification of shareholders and other factors and subject to the provisions for amendment to the instruments of incorporation of the Fund.

| | **Easternmed Equities Fund Class A 30 June 2026 Number of shares** | **Easternmed Equities Fund Class A 30 June 2026 €** | Easternmed Equities Fund Class A 31 December 2025 Number of shares | Easternmed Equities Fund Class A 31 December 2025 € |
|---|---|---|---|---|
| **Issued and fully paid** | | | | |
| Balance at 1 January | **2.759.664** | **597.611.820** | 2.513.691 | 473.086.971 |
| Increase in net assets attributable to holders of investor shares | **-** | **60.928.490** | - | 75.985.221 |
| Issue of investor shares during the period/year | **35.671** | **8.542.476** | 245.973 | 48.539.628 |
| **Balance at 30 June / 31 December** | **2.795.335** | **667.082.786** | 2.759.664 | 597.611.820 |

### 14. Net assets attributable to holders of investor shares (continued)

The rights attaching to the investor shares are as follows:

- The shares may be redeemed daily at the net asset value per share of the respective class.
- The shares carry a right to receive notice of, attend and vote at general meetings.
- The holders of investor shares are entitled to receive all dividends declared and paid by the Fund. On winding-up, the holders are entitled to a return of capital based on the net asset value per share of their respective classes and if applicable to the class the subscription, and redemption fee.

### 15. Other payables

| | **Easternmed Equities Fund Class A 30 June 2026** | Easternmed Equities Fund Class A 31 December 2025 |
|---|---|---|
| | **€** | € |
| Accruals | **172.289** | 150.987 |
| Other creditors | **-** | 14.036 |
| Payables to related companies (Note 17.3) | **169.416** | 147.047 |
| | **341.705** | 312.070 |

### 16. Current tax liabilities

| | **Easternmed Equities Fund Class A 30 June 2026** | Easternmed Equities Fund Class A 31 December 2025 |
|---|---|---|
| | **€** | € |
| Corporation tax | **17.565** | 11.466 |
| | **17.565** | 11.466 |

### 17. Related party balances and transactions

The related party balances and transactions are as follows:

#### 17.1 Management Company

The Fund has appointed the Management Company to provide management services pursuant to a management agreement dated 9 June 2016. Under the terms of the agreement the Fund pays the Management Company 0,50% per annum for Class A investor shares and 1% per annum for Class B investor shares, currently not active, of the average net asset value of the Fund for the relevant fiscal year, for managing the Fund. The management fee is computed daily on the daily value of the Fund's net assets and is paid by debiting it from the Fund at the end of each month. The management fee includes fees to enable the Management Company to perform its tasks and functions, or to provide services, irrespective of whether those functions is carried out by the Management Company itself or have been outsourced to third parties.

On 20 December 2019, an addendum of the management agreement dated 9 June 2016 was signed. The management fee the Fund pays the Management Company for Class A investor shares decreased to 0,30% from 0,50% with effective date 1 January 2020. The Prospectus has been amended accordingly and the holders of investor shares have been informed via email.

### 17. Related party balances and transactions (continued)

On 30 July 2021, a second addendum of the management agreement dated 9 June 2016 was signed. The management fee the Fund pays the Management Company for Class A investor shares decreased to 0,20% from 0,30% with effective date 1 August 2021. The Prospectus has been amended accordingly and the holders of investor shares have been informed via email.

On 31 March 2022, a third addendum of the management agreement dated 9 June 2016 was signed. The management fee the Fund pays the Management Company for Class A investor shares decreased to 0,15% from 0,20% with effective date 1 April 2022. The Prospectus has been amended accordingly and the holders of investor shares have been informed via email.

The management fees for the six months ended 30 June 2026 totaled €483.920 (30 June 2025: €385.362) and are presented in the statement of comprehensive income. The amount outstanding at the period end is €250.050 (31 December 2025: €220.343) and it is included in accruals and other creditors in other payables.

At 30 June 2026, 10.000 Class A investor shares were held by the Management Company.

### 17.2 Directors' remuneration

The directors' fees for the six months ended 30 June 2026 totaled €4.785 (30 June 2025: €4.785) and are presented in the statement of comprehensive income. The amount outstanding at the period end is €893 (31 December 2025: €2.353) and it is included in accruals in other creditors. Directors' remuneration consisted of only fixed directors' fees.

### 17.3 Payables to related parties (Note 15)

| Name | Nature of transactions | **Easternmed Equities Fund Class A 30 June 2026 €** | Easternmed Equities Fund Class A 31 December 2025 € |
|---|---|---|---|
| Easternmed Asset Management Services Ltd | Trade | **162.047** | 140.038 |
| Easternmed Asset Management Services Ltd | Other | **7.369** | 7.009 |
| | | **169.416** | 147.047 |

The payables to related parties were provided interest free, and there was no specified repayment date.

### 18. Other key contracts

The Fund has appointed the Administrator to provide administrative services pursuant to an administration agreement dated 9 June 2016. Under the terms of the agreement the Fund pays the Administrator 0,05% per annum of the average net asset value of the Fund for the relevant fiscal year, with a floor of €12.500 and a ceiling of €50.000 per annum. On 18 March 2025, an addendum of the administration agreement was signed. The administration fee ceiling increased to €65.000. The administration fee is computed daily on the daily value of the Fund's net assets and is billed at the end of each month. The administrative fees for the six months ended 30 June 2026 totaled €32.500 (30 June 2025: €32.500) and are presented in the statement of comprehensive income. The amount outstanding at the period end is €11.130 (31 December 2025: €11.683) and it is included in accruals in other payables.

**18. Other key contracts (continued)**

The Fund has appointed the Depositary to provide depositary services pursuant to a depositary agreement dated 9 June 2016. Under the terms of the agreement the Fund pays the depositary 0,05% per annum of the average net value of the Fund's assets held by the Depositary during the relevant fiscal year with a minimum fee of €2.500 per quarter. On 28 June 2024, an addendum of the depositary agreement was signed. The fee has been reduced to a scaling fee of 0,05% for the first €50 million, 0,0425% for the next €250 million and 0,035% for amounts above €300 million of the average net assets of the Fund. The Depositary's fee is computed daily on the daily valuation of the net assets held by the Depositary and billed at the end of each quarter. This fee includes Depositary fees which may be payable to third parties who undertake to safeguard all or part of the assets of the Fund on the basis of outsourcing arrangements. The Depositary fees for the six months ended 30 June 2026 totaled €132.298 (30 June 2025: €107.601) and are presented in the statement of comprehensive income. The amount outstanding at the period end is €65.622 (31 December 2025: €50.330) and it is included in accruals in other payables.